Tag: calcitonin gene-related peptide (CGRP) receptor antagonists

1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...